Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure

The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the effect of lenacapavir on HIV capsid stability and uncoating. We employ a single particle app...

Celý popis

Podrobná bibliografie

Hlavní autoři:	KM Rifat Faysal, James C Walsh, Nadine Renner, Chantal L Márquez, Vaibhav B Shah, Andrew J Tuckwell, Michelle P Christie, Michael W Parker, Stuart G Turville, Greg J Towers, Leo C James, David A Jacques, Till Böcking
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	eLife Sciences Publications Ltd 2024-02-01
Edice:	eLife
Témata:	HIV-1 capsid drug mechanism of action
On-line přístup:	https://elifesciences.org/articles/83605
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!